Floatz logo

5-azacytidine

Recurrent T-Cell Non-Hodgkin Lymphoma

National Cancer Institute (NCI)Phase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Recurrent T-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
cc-5013
Samsung Medical Center
Phase 2BB
Cyclophosphamide
GC Cell Corporation
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Memorial Sloan Kettering Cancer Center
Phase 2BB
TACROLIMUS
M.D. Anderson Cancer Center
Phase 2BB
Busulphan
Sichuan University
Phase 3BB

View all 23 →

Same molecule, other indications

5-azacytidine is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BB
Indicative ·
70 / 100
View asset →
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →